NCT01937260View on ClinicalTrials.gov

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions
Psoriasis
Interventions
DRUG

Brodalumab

Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.

Trial Locations (10)

1010

Research Site, Grafton, Auckland

3181

Research Site, Prahran

4006

Research Site, Herston

5000

Research Site, Adelaide

8011

Research Site, Christchurch

34471

Research Site, Ocala

75231

Research Site, Dallas

78759

Research Site, Austin

92697

Research Site, Irvine

92801

Research Site, Anaheim

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT01937260 - Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects | Biotech Hunter | Biotech Hunter